Lack of pharmacokinetic interaction between intravenous 2',3'-dideoxyinosine and 3'-azido-3'-deoxythymidine in rats.
作者信息
Wientjes M G, Au J L
机构信息
Department of Surgery, Comprehensive Cancer Center, Columbus, Ohio.
出版信息
Antimicrob Agents Chemother. 1992 Mar;36(3):665-8. doi: 10.1128/AAC.36.3.665.
Abstract
We investigated the pharmacokinetic interaction between 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxyinosine (ddI), given to rats by intravenous injection. For both compounds, the clearances, terminal half-lives, and fractions of the dose excreted unchanged in urine were not altered by the other drug (P greater than 0.05), indicating no pharmacokinetic interaction between the two drugs.
摘要
相似文献
1
Lack of pharmacokinetic interaction between intravenous 2',3'-dideoxyinosine and 3'-azido-3'-deoxythymidine in rats.
Antimicrob Agents Chemother. 1992 Mar;36(3):665-8. doi: 10.1128/AAC.36.3.665.
2
Comparative metabolism of the antiviral dimer 3'-azido-3'-deoxythymidine-P-2',3'-dideoxyinosine and the monomers zidovudine and didanosine by rat, monkey, and human hepatocytes.
Antimicrob Agents Chemother. 1997 Nov;41(11):2502-10. doi: 10.1128/AAC.41.11.2502.
3
Phase I dose-escalation pharmacokinetics of AZT-P-ddI (IVX-E-59) in patients with human immunodeficiency virus.
J Clin Pharmacol. 1997 Mar;37(3):201-13. doi: 10.1002/j.1552-4604.1997.tb04782.x.
4
Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection.
Br J Clin Pharmacol. 1995 May;39(5):527-30. doi: 10.1111/j.1365-2125.1995.tb04490.x.
5
Pharmacokinetic evaluation of drug interactions with anti-HIV drugs, II: Effect of 2',3'-dideoxyinosine (ddI) on zidovudine kinetics in monkeys.
AIDS Res Hum Retroviruses. 1992 Feb;8(2):277-83. doi: 10.1089/aid.1992.8.277.
6
7
Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome.
Br J Clin Pharmacol. 1994 May;37(5):421-6. doi: 10.1111/j.1365-2125.1994.tb05708.x.
8
Distributed model analysis of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine distribution in brain tissue and cerebrospinal fluid.
J Pharmacol Exp Ther. 1997 Sep;282(3):1509-17.
9
Pharmacokinetics of anti-HIV nucleosides in microswine.
J Pharm Pharmacol. 1991 Dec;43(12):823-6. doi: 10.1111/j.2042-7158.1991.tb03187.x.
10
Nonlinear disposition of intravenous 2',3'-dideoxyinosine in rats.
Pharm Res. 1992 Aug;9(8):1070-5. doi: 10.1023/a:1015866714224.
引用本文的文献
1
Renal disposition and drug interaction screening of (-)-2'-deoxy-3'-thiacytidine (3TC) in the isolated perfused rat kidney.
Pharm Res. 1995 Dec;12(12):1958-63. doi: 10.1023/a:1016252225013.
2
Efflux of zidovudine and 2',3'-dideoxyinosine out of the cerebrospinal fluid when administered alone and in combination to Macaca nemestrina.
Pharm Res. 1994 Feb;11(2):312-7. doi: 10.1023/a:1018928013044.
3
Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome.
Br J Clin Pharmacol. 1994 May;37(5):421-6. doi: 10.1111/j.1365-2125.1994.tb05708.x.
4
Effect of zidovudine on transplacental pharmacokinetics of ddI in the pigtailed macaque (Macaca nemestrina).
Antimicrob Agents Chemother. 1995 Feb;39(2):343-5. doi: 10.1128/AAC.39.2.343.
5
Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection.
Br J Clin Pharmacol. 1995 May;39(5):527-30. doi: 10.1111/j.1365-2125.1995.tb04490.x.
本文引用的文献
1
Human erythrocytic purine nucleoside phosphorylase: reaction with sugar-modified nucleoside substrates.
Biochemistry. 1980 Jan 8;19(1):102-7. doi: 10.1021/bi00542a016.
2
Statistical estimations in pharmacokinetics.
J Pharmacokinet Biopharm. 1974 Apr;2(2):123-48. doi: 10.1007/BF01061504.
3
Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases.
Clin Pharmacol Ther. 1987 Apr;41(4):407-12. doi: 10.1038/clpt.1987.49.
4
Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report.
N Engl J Med. 1987 Feb 26;316(9):557-64. doi: 10.1056/NEJM198702263160925.
5
Initial studies on the cellular pharmacology of 2',3'-dideoxyadenosine, an inhibitor of HTLV-III infectivity.
Biochem Pharmacol. 1987 Jun 1;36(11):1765-8. doi: 10.1016/0006-2952(87)90235-8.
6
Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.
Lancet. 1986 Mar 15;1(8481):575-80. doi: 10.1016/s0140-6736(86)92808-4.
7
Pharmacokinetics and saturable renal tubular secretion of zidovudine in rats.
J Pharm Sci. 1989 Jul;78(7):530-4. doi: 10.1002/jps.2600780704.
8
Phosphorylation of 2',3'-dideoxyinosine by cytosolic 5'-nucleotidase of human lymphoid cells.
Mol Pharmacol. 1989 Aug;36(2):291-5.
9
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.
Proc Natl Acad Sci U S A. 1986 Nov;83(21):8333-7. doi: 10.1073/pnas.83.21.8333.
10
Initial clinical experience with dideoxynucleosides as single agents and in combination therapy.
Ann N Y Acad Sci. 1990;616:328-43. doi: 10.1111/j.1749-6632.1990.tb17853.x.
Zotero 插件